High transforming growth factor β expression represents an important prognostic parameter for surgically resected non-small cell lung cancer

Human Pathology

Volumn 43, Issue 3, 2012, Pages 339-349

  Sterlacci, William ^a   Wolf, Dominik ^b   Savic, Spasenija ^c   Hilbe, Wolfgang ^b   Schmid, Thomas ^d   Jamnig, Herbert ^e   Fiegl, Michael ^b   Tzankov, Alexandar ^c  

^a University Teaching Hospital Feldkirch   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e Natters Hospital   (Austria)

Author keywords

Non small cell lung cancer; TGF ; Tumor immunity; Tumor microenvironment

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GRANZYME B; PROGRAMMED DEATH 1 LIGAND 1; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRYPTASE;

ARTICLE; B CELL LYMPHOMA; CANCER SURGERY; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PARAMETERS; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR MICROENVIRONMENT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AUSTRIA; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; YOUNG ADULT;

EID: 84857037901     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.05.017     Document Type: Article

References (36)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics 2009 CA Cancer J Clin 59 2009 225 249
2. M.M. Van den Heuvel, S.A. Burgers, and N. van Zandwijk Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination Clin Lung Cancer 10 2009 99 105
3. K. Milne, M. Köbel, and S.E. Kalloger Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors PLoS One 4 2009 e6412
4. H.Y. Park, L.M. Wakefield, and M. Mamura Regulation of tumor immune surveillance and tumor immune subversion by TGF-beta Immune Netw 9 2009 122 126
5. W. Zhang, K. Wu, and W. He Transforming growth factor beta 1 plays an important role in inducing CD4(+) CD25(+) forkhead box P3(+) regulatory T cells by mast cells Clin Exp Immunol 161 2010 490 496
6. T. Groot Kormelink, A. Abudukelimu, and F.A. Redegeld Mast cells as target in cancer therapy Curr Pharm Des 15 2009 1868 1878
7. - cells through SDF-1/CXCR4 interaction J Exp Clin Cancer Res 29 2010 80
8. + regulatory T cells that traffic through CXCL12/CXCR4 signals Cancer Res 64 2004 8451 8455 (Pubitemid 39491786)
9. + T cell tolerance through PD-1 and CTLA-4 Nat Immunol 6 2005 280 286 (Pubitemid 41724765)
10. S. Muenst, S. Hoeller, S. Dirnhofer, and A. Tzankov Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival Hum Pathol 40 2009 1715 1722
11. W. Travis, E. Brambilla, H. Müller-Hermelink, and C. Harris Pathology and genetics of tumours of the lung, pleura, thymus and heart 2004 IARCPress Lyon, France
12. W. Sterlacci, M. Fiegl, W. Hilbe, J. Auberger, G. Mikuz, and A. Tzankov Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases Virchows Arch 455 2009 125 132
13. W. Sterlacci, A. Tzankov, and L. Veits The prognostic impact of sex for surgically resected non-small cell lung cancer depends on clinicopathological characteristics Am J Clin Pathol 135 2011 611 618
14. M. Fiegl, W. Hilbe, and J. Auberger Twelve-year retrospective analysis of lung cancer-the TYROL study: daily routine in 1,424 patients (1995-2006) J Clin Oncol 26 2008 abstr 19063
15. W. Hilbe, K. Aigner, and C. Dittrich Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms Wien Klin Wochenschr 119 2007 259 266 (Pubitemid 46895797)
16. W. Sterlacci, M. Fiegl, and W. Hilbe Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients J Thorac Oncol 5 2010 1325 1336
17. A. Tzankov, I. Zlobec, P. Went, H. Robl, S. Hoeller, and S. Dirnhofer Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores Leuk Lymphoma 51 2010 199 212
18. N.M. Moutsopoulos, J. Wen, and S.M. Wahl TGF-beta and tumors-an ill-fated alliance Curr Opin Immunol 20 2008 234 240
19. E. Meulmeester, and P. Ten Dijke The dynamic roles of TGF-β in cancer J Pathol 223 2011 205 218 10.1002/path.2785
20. T. Fukuyama, Y. Ichiki, and S. Yamada Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/ immunological responses both in vivo and in vitro Cancer Sci 98 2007 1048 1054 (Pubitemid 46865390)
21. Y. Hasegawa, S. Takanashi, Y. Kanehira, T. Tsushima, T. Imai, and K. Okumura Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma Cancer 91 2001 964 971
22. W.D. Travis, E. Brambilla, and M. Noguchi International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 2011 244 285
23. N. Ramnath, D. Tan, and Q. Li Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 55 2006 891 899 (Pubitemid 43673578)
24. S.H. Wrzesinski, Y.Y. Wan, and R.A. Flavell Transforming growth factor-beta and the immune response: implications for anticancer therapy Clin Cancer Res 13 2007 5262 5270 (Pubitemid 47510349)
25. + T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis Tohoku J Exp Med 191 2000 113 118
26. + ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells Cancer Immunol Immunother 52 2003 423 428 (Pubitemid 36831363)
27. N.P. Restifo, F. Esquivel, and Y. Kawakami Identification of human cancers deficient in antigen processing J Exp Med 177 1993 265 272 (Pubitemid 23117076)
28. P.A. Ascierto, M. Napolitano, and E. Celentano Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment J Transl Med 8 2010 76
29. +) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy J Immunother 33 2010 435 441
30. + regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer J Thorac Oncol 5 2010 585 590
31. D. Wolf, A.M. Wolf, and H. Rumpold The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer Clin Cancer Res 11 2005 8326 8331 (Pubitemid 41746944)
32. A.M. Wolf, D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, and B. Grubeck-Loebenstein Increase of regulatory T cells in the peripheral blood of cancer patients Clin Cancer Res 9 2003 606 612 (Pubitemid 36182591)
33. W. Zou Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat Rev Cancer 5 2005 263 274 (Pubitemid 40488632)
34. H. Imai, N. Sunaga, and Y. Shimizu Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer Int J Immunopathol Pharmacol 23 2010 153 164
35. + T lymphocytes in human non-small cell lung cancer Cell Mol Immunol 7 2010 389 395
36. K. Sakuishi, L. Apetoh, J.M. Sullivan, B.R. Blazar, V.K. Kuchroo, and A.C. Anderson Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity J Exp Med 207 2010 2187 2194